Danaher Co. (NYSE:DHR) Shares Bought by Affiance Financial LLC

Affiance Financial LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 10.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,135 shares of the conglomerate’s stock after buying an additional 111 shares during the quarter. Affiance Financial LLC’s holdings in Danaher were worth $284,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Danaher by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 1,233,726 shares of the conglomerate’s stock valued at $308,246,000 after acquiring an additional 11,438 shares during the last quarter. Rockline Wealth Management LLC increased its position in Danaher by 19.4% during the second quarter. Rockline Wealth Management LLC now owns 5,778 shares of the conglomerate’s stock worth $1,444,000 after purchasing an additional 940 shares during the last quarter. Klingenstein Fields & Co. LP raised its stake in Danaher by 0.7% during the second quarter. Klingenstein Fields & Co. LP now owns 55,205 shares of the conglomerate’s stock worth $13,793,000 after purchasing an additional 403 shares during the period. Versor Investments LP acquired a new position in shares of Danaher in the 2nd quarter valued at $206,000. Finally, CIBC Asset Management Inc grew its stake in shares of Danaher by 53.9% during the 2nd quarter. CIBC Asset Management Inc now owns 198,277 shares of the conglomerate’s stock valued at $49,540,000 after buying an additional 69,410 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DHR shares. Royal Bank of Canada lifted their price objective on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Barclays boosted their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Robert W. Baird upped their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group initiated coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last quarter. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 0.9 %

Shares of NYSE:DHR opened at $269.31 on Tuesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company’s fifty day moving average is $260.30 and its two-hundred day moving average is $255.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $194.50 billion, a price-to-earnings ratio of 45.65, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 earnings per share. Equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.